Rapid and efficient screening of primary B cells to identify target-specific antibodies
Discover how Merck used the Cyto-Mine® to screen primary B cells (human and rodent cells) for antibodies specific to certain antigens.
The advancement of therapeutic antibody discovery faces time and cost challenges. Merck R&D scientists address this by employing Sphere Bio’ microfluidics picodroplet technology.
Rapid high-throughput screening of primary antibody-secreting cells from rodent and human donors, demonstrating specific antibody binding to recombinant antigens, showcases the streamlined and automated workflow of the Cyto-Mine® platform in antibody discovery projects.
Key takeaways within this application note:
- Human plasma blasts post-tetanus toxoid vaccination were isolated and screened to identify tetanus-specific antibodies.
- Cyto-Mine® was used on rodent B cells immunized with Cancer Related Antigen (CRA) to explore immune response diversity.
- This app note demonstrates the ability to process millions of cells efficiently in a single day, accelerating the antibody discovery process.
Download to continue reading…
The Next Generation: Cyto-Mine® Chroma
Automate. Accelerate. Analyze millions of cells in a single day.
Think Cyto-Mine®, but supercharged, enabling multiplexing and greater assay flexibility to fit your needs. It means that you can examine vastly greater numbers of cells — and isolate the most valuable ones— with unparalleled precision.
Cyto-Mine® Chroma
Contact sales
